Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients

Stroke Clinical Trial

Official title:

Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02208466
• Other study ID #: 2014P001046
• Status: Completed
• Phase: Phase 2
• Start date: September 2014
• Est. completion date: June 25, 2019

Study information

• Verified date: February 2021
• Source: Spaulding Rehabilitation Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study investigator's aim to assess the effect of a type of non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) in conjunction with fluoxetine on motor recovery after stroke.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: June 25, 2019
• Est. primary completion date: June 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ischemic infarction within the past 2 years post event that has caused hemiparesis or hemiplegia, as self-reported and/or confirmed by medical record.
• Older than 18 years old.
• Upper extremity weakness defined as a score of >11 and =56 on the arm motor Fugl-Mayer motor scale.
• Minimal pre-stroke disability defined as a score of <3 in the Modified Rankin Scale.
• Subjects need to be able to follow directions and participate in 2 hours of testing with short breaks.
• Subjects need to be able to provide informed consent.

Exclusion Criteria:

• Any substantial decrease in alertness, language reception, or attention that might interfere with understanding instruction for motor testing
• Excessive pain in any joint of the paretic extremity (not applicable to severe stroke subjects), as self reported
• Contraindications to single pulse TMS (will be used to measure cortical excitability) such as: history of seizures, unexplained loss of consciousness, any metal implants in the head, frequent or severe headaches or neck pain, any other electronic implanted medical devices such as pacemakers, defibrillators, or implant medication pump.
• Patients who have taken fluoxetine in the past 5 weeks.
• Patients taking any other SSRI at the time of enrollment or in the previous month.
• Patients taking any other medication likely to have adverse interaction with SSRIs (all the medications the patient is taking will be carefully reviewed, as noted below in "Monitoring of important drug interactions").
• Active depression on admission to SRH defined by a score of 24 or higher in the Hamilton Depression Rating Scale (HAM-D)
• Concurrent medical condition likely to worsen patient's functional status in the next 6 months such as: cancer, terminal heart, kidney or liver disease, as self-reported and/or confirmed by medical record.
• Pregnancy.

Related Conditions & MeSH terms

• Motor Function
• Stroke

Intervention

Device:
• Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.

Drug:
• Fluoxetine
Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.

Device:
• Sham repetitive transcranial magnetic stimulation (rTMS)
Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.

Drug:
• Placebo Fluoxetine
Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.

Locations

Country	Name	City	State
United States	Spaulding Rehabilitation Hospital	Charlestown	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Spaulding Rehabilitation Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Motor Function (Jebsen-Taylor Task)	Jebsen Taylor Hand Function Test: measures hand function in real-life activities, by evaluating the time required to perform 7 different tasks. We used the non-constrained hand for the assessments. The sum of the different tasks was used for the analysis.; Calculation details: value at 9 months minus value at baseline, change in seconds (adjusted mean difference).	baseline and 90 days
Primary	Changes in Fugl-Meyer Assessment (FMA) Scale	The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation, and joint functioning in patients with post-stroke hemiplegia. We used the upper limb motor function subscale: minimum values= 0 ; maximum values= 66. Higher scores mean a better outcome. Changes from baseline to 90 days (value at 90 days minus value at baseline).	baseline and 90 days
Secondary	Changes in Cortical Excitability Measures	We will measure cortical excitability using single-pulsed transcranial magnetic stimulation (TMS) before and after stimulation at three different time-points. Changes from baseline to 90 days (value at 90 days minus value at baseline).	Baseline and 90 days